Medpace
MEDP
604.25
+1.35
+0.22%
Medpace
US · MEDP
#1015 by market cap
Listed 2016
604.25
+1.35
+0.22%
Live - 5344 symbols - heartbeat 518s ago
· 2026-10-08 07:38
Pre-market
604.25
0.00%
After-hours
604.25
0.00%
Overnight
604.25
0.00%
- Market cap
- 16.87B
- P/E (TTM)i
- 35.50
- P/Bi
- 38.87
- EPSi
- 15.28
- Div yieldi
- 0.00%
- 52W posi
- 76%
Reader sentiment
Are you bullish or bearish on MEDP?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 8.31, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +19.97% YoY
Margins
- Gross margin
- 30.06%
- Operating margin
- 21.14%
- Net margin
- 17.83%
Key ratios & quality
- PEG ratioi
- 1.58
- Altman Z-Scorei
- 8.31
PEG uses trailing P/E against the 3-year net income growth rate (22.51%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 704.59M | 860.97M | 925.93M | 1.14B | 1.46B | 1.89B | 2.11B | 2.53B |
| Gross profit | 215.53M | 245.70M | 278.73M | 328.16M | 432.44M | 524.51M | 656.31M | 760.62M |
| Selling & admin expenses | 75.68M | 95.25M | 92.16M | 108.42M | 131.40M | 161.35M | 180.18M | 197.56M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 101.05M | 127.26M | 167.04M | 198.62M | 278.70M | 336.83M | 446.87M | 534.94M |
| Pretax profit | 93.95M | 124.83M | 168.53M | 201.85M | 282.86M | 335.68M | 475.92M | 542.38M |
| Tax | 20.77M | 24.39M | 23.15M | 20.00M | 37.49M | 52.87M | 71.54M | 91.25M |
| Net profit | 73.19M | 100.44M | 145.38M | 181.85M | 245.37M | 282.81M | 404.39M | 451.12M |
| Basic EPS | 2 | 3 | 4 | 5 | 8 | 9 | 13 | 16 |
| Diluted EPS | 1.97 | 2.67 | 3.84 | 4.81 | 7.28 | 8.88 | 12.63 | 15.28 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 558.57M | 603.31M | 659.90M | 708.45M | 706.60M | 707.33M |
| Gross profit | 178.35M | 180.01M | 196.94M | 205.32M | 196.33M | 201.64M |
| Selling & admin expenses | 57.90M | 46.66M | 48.08M | 44.92M | 47.92M | 48.10M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 113.52M | 126.34M | 141.81M | 153.27M | 141.50M | 146.82M |
| Pretax profit | 118.17M | 124.54M | 142.84M | 156.83M | 147.59M | 151.66M |
| Tax | 3.58M | 34.28M | 31.70M | 21.70M | 23.72M | 30.30M |
| Net profit | 114.60M | 90.26M | 111.14M | 135.13M | 123.87M | 121.36M |
| Basic EPS | 4 | 3 | 4 | 5 | 4 | 4 |
| Diluted EPS | 3.67 | 3.10 | 3.86 | 4.67 | 4.28 | 4.25 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 178.11M | 317.03M | 473.65M | 690.91M | 333.96M | 593.83M | 1.03B | 989.62M |
| Cash & ST investments | 23.28M | 131.92M | 277.77M | 461.30M | 28.27M | 245.45M | 669.44M | 497.05M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 967.93M | 1.14B | 1.39B | 1.66B | 1.35B | 1.66B | 2.10B | 1.98B |
| Total current liabilities | 257.03M | 343.00M | 440.11M | 557.22M | 803.47M | 925.13M | 1.10B | 1.34B |
| Short-term debt | -- | -- | -- | -- | 50.00M | -- | -- | -- |
| Long-term debt | 79.72M | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 378,230,000.00 | 416,788,000.00 | 584,898,000.00 | 707,007,000.00 | 966,108,000.00 | 1,097,878,000.00 | 1,275,321,000.00 | 1,516,401,000.00 |
| Total equity | 589.70M | 726.28M | 805.78M | 952.93M | 386.39M | 558.95M | 825.55M | 459.07M |
| Retained earnings | -41.49M | 68.11M | 115.23M | 234.98M | -359.83M | -221.65M | 8.17M | -459.98M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 821.44M | 520.81M | 737.29M | 989.62M | 1.14B | 1.05B |
| Cash & ST investments | 441.44M | 46.33M | 285.35M | 497.05M | 652.68M | 502.69M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 1.90B | 1.57B | 1.75B | 1.98B | 2.13B | 2.06B |
| Total current liabilities | 1.12B | 1.22B | 1.28B | 1.34B | 1.35B | 1.44B |
| Short-term debt | -- | -- | -- | -- | -- | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 1,303,760,000.00 | 1,399,322,000.00 | 1,459,371,000.00 | 1,516,401,000.00 | 1,531,299,000.00 | 1,623,320,000.00 |
| Total equity | 593.61M | 172.35M | 293.64M | 459.07M | 598.31M | 433.86M |
| Retained earnings | -269.72M | -703.22M | -596.24M | -459.98M | -336.11M | -511.37M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 156.58M | 201.87M | 258.68M | 263.33M | 388.05M | 433.37M | 608.82M | 713.22M |
| Depreciation & amortization | 38.80M | 23.19M | 19.53M | 21.12M | 22.34M | 26.33M | 29.25M | 28.12M |
| Free cash flow | 140.56M | 183.96M | 227.34M | 235.06M | 351.17M | 396.73M | 572.27M | 681.87M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | -98.27M | -62.10M | -847.85M | -144.02M | -169.87M | -917.39M |
| Ending cash balance | 23.28M | 131.92M | 277.77M | 461.30M | 28.27M | 245.45M | 669.44M | 497.05M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 125.84M | 148.53M | 246.21M | 192.65M | 151.79M | 162.01M |
| Depreciation & amortization | 6.93M | 7.01M | 7.05M | 7.13M | 6.91M | 6.71M |
| Free cash flow | 115.84M | 142.41M | 235.50M | 188.12M | 144.97M | 138.10M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -371.90M | -540.92M | -4.57M | 0 | 0 | -294.76M |
| Ending cash balance | 441.44M | 46.33M | 285.35M | 497.05M | 652.68M | 502.69M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 13.34 | 15.22 | 18.92 | 20.63 | 36.62 | 59.79 | 58.41 | 70.23 |
| ROA %i | 7.60 | 9.49 | 11.44 | 11.89 | 16.28 | 18.78 | 21.52 | 22.13 |
| ROIC %i | 11.50 | 14.08 | 17.13 | 18.10 | 28.69 | 46.09 | 48.93 | 59.18 |
| 5-year avg ROE %i | -- | 7.21 | 11.42 | 15.02 | 20.94 | 30.24 | 38.87 | 49.14 |
| EBIT margin %i | 14.49 | 14.68 | 18.04 | 17.39 | 19.09 | 17.86 | 21.19 | 21.14 |
| FCF / sales %i | 19.95 | 21.37 | 24.55 | 20.58 | 24.05 | 21.04 | 27.13 | 26.95 |
| Current ratioi | 0.69 | 0.92 | 1.08 | 1.24 | 0.42 | 0.64 | 0.93 | 0.74 |
| Quick ratioi | 0.61 | 0.84 | 1.00 | 1.16 | 0.35 | 0.59 | 0.87 | 0.67 |
| Debt / assetsi | 8.24 | 3.96 | 8.28 | 7.89 | 13.96 | 8.58 | 6.01 | 5.75 |
| LT debt / equityi | 13.52 | 6.23 | 14.29 | 13.74 | 35.94 | 25.43 | 15.29 | 24.76 |
| Interest coveragei | 12.52 | 80.61 | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | 25.20 | 26.87 | 28.52 | 17.48 | 19.25 | 26.76 | 22.68 | 20.12 |
| Net income CAGR (3Y) %i | -- | 95.58 | 54.89 | 35.44 | 34.68 | 24.83 | 30.53 | 22.51 |
| FCF CAGR (3Y) %i | 20.97 | 33.00 | 38.76 | 18.70 | 24.05 | 20.39 | 34.53 | 24.76 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 65.82 | 89.38 | 73.70 | 70.23 | 77.25 | 162.15 |
| ROA %i | 22.55 | 23.96 | 22.57 | 22.13 | 22.87 | 27.09 |
| ROIC %i | 54.50 | 70.14 | 60.88 | 59.18 | 63.91 | 115.48 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 21.16 | 21.40 | 21.50 | 21.14 | 21.02 | 20.97 |
| FCF / sales %i | 25.08 | 25.98 | 28.70 | 26.95 | 26.55 | 25.40 |
| Current ratioi | 0.73 | 0.43 | 0.57 | 0.74 | 0.85 | 0.73 |
| Quick ratioi | 0.66 | 0.35 | 0.51 | 0.67 | 0.78 | 0.66 |
| Debt / assetsi | 6.68 | 7.95 | 6.79 | 5.75 | 5.74 | 5.84 |
| LT debt / equityi | 21.34 | 72.50 | 40.55 | 24.76 | 20.43 | 27.68 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Single segment100.00%
Quote time 2026-10-08 07:38:54 · For reference only, not investment advice and not tailored to your situation.